#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Cushing's syndrome Juvenile chronic myelomonocytic leukaemia Gestational trophoblastic tumour Polycystic liver disease Hyperchylomicronaemia Endometrial cancer Erythema multiforme Carcinoid syndrome Alagille syndrome Andersen-Tawil syndrome Chronic myelomonocytic leukaemia Thalassaemia Non-small cell lung cancer metastatic Alport's syndrome Biliary cancer metastatic More trials…

    Learn about Rare Diseases

    Adrenogenital syndrome Advanced systemic mastocytosis Usher’s syndrome Ocular melanoma – Diagnostics Hairy cell leukaemia – Basic Information Atypical haemolytic uraemic syndrome – Trials in Disease Stevens-Johnson syndrome – Trials in Disease Carcinoid syndrome – Diagnostics Hereditary hypophosphataemic rickets – Basic Information Sarcoidosis – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Toldc Rugonersen Zinc Acexamate Abc-23B-116 SILYMARIN Gen1047 Arachis Hypogaea Extract Atacicept Astegolimab Magrolimab Nizatidine Flucloxacillin Zinc Oxide Lorazepam Vaborbactam Metronidazole Clascoterone Agrostis Stolonifera Pollen Danazol Mezigdomide More therapies…

    Learn about Your Condition

    Tympanic membrane hyperaemia Liver transplant rejection Persistent depressive disorder Cholangitis sclerosing Paedophilia Pre-eclampsia Anorexia nervosa Colon cancer stage II Dyslipidaemia Palmoplantar pustulosis Crohn's disease Small for dates baby Pyelonephritis Vestibular disorder Testicular germ cell cancer More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Centre Hospitalier Universitaire Amiens Picardie

Centre Hospitalier Universitaire Amiens Picardie

1 Place Victor Pauchet, Amiens, 80080, France

Want to learn more about this study or check if you can participate? Contact us.

  • Study on the Effectiveness and Safety of Bemcentinib for Hospitalized Patients with Moderate COVID-19

    Not recruiting

    2 1
    Investigated Diseases:
    • Lung disorder
    Investigated Drugs:
    • Bemcentinib
    Belgium Czechia France Greece Ireland Italy +4

  • Study Comparing Vasopressin and Noradrenaline for Patients with Vasoplegic Syndrome Undergoing Cardiac Surgery with Extracorporeal Circulation

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Argipressin
    • Noradrenaline Tartrate
    France

  • Study of Ezurpimtrostat with Atezolizumab and Bevacizumab for Patients with Unresectable Liver Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Hepatocellular carcinoma
    Investigated Drugs:
    • Gns561
    • Atezolizumab
    • Bevacizumab
    France

  • Study on the Safety and Effectiveness of Stereotactic Body Radiotherapy with or without Pembrolizumab for Patients with Unresected Stage I or II Non-Small Cell Lung Cancer

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Pembrolizumab
    Austria France Germany Hungary Italy The Netherlands +4

  • Long-Term Safety Study of HepaStem for Patients with Urea Cycle Disorders, Crigler-Najjar Syndrome, and Fibroinflammatory Liver Diseases

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Acute hepatic failure
    • Inborn error of metabolism
    • Urea cycle disorder
    Investigated Drugs:
    • Hhalpc
    Belgium Bulgaria France Poland Spain

  • Study of Pembrolizumab in Patients with Esophageal Cancer Undergoing Chemoradiotherapy

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Oesophageal carcinoma
    Investigated Drugs:
    • Calcium Folinate
    • Cisplatin
    • Fluorouracil
    Belgium Czechia Denmark Estonia France Germany +4

  • Study on the Effectiveness and Safety of Imipenem, Cilastatin, and XNW4107 for Adults with Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Pneumonia bacterial
    Investigated Drugs:
    • (1R,4S)-4-(5-((S)-2-Iminioimidazolidin-4-Yl)-1,3,4- Oxadiazol-2-Yl)-6-Oxo-5,7- Diazaspiro[Bicyclo[3.2.1]Octane-2,1′-Cyclopropan]-7-Yl Sulfate
    • Imipenem
    • Relebactam
    France Spain

  • Study on Azacitidine and Gilteritinib for Adults with Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Acute myeloid leukaemia
    Investigated Drugs:
    • Gilteritinib
    • Azacitidine
    France

  • Study on the Effects of Obefazimod for Patients with Moderate to Severe Ulcerative Colitis

    Not recruiting

    3 1
    Investigated Drugs:
    • Obefazimod
    Belgium Bulgaria Croatia Czechia France Germany +8

  • Study of Pembrolizumab with Chemoradiotherapy for Patients with Muscle-Invasive Bladder Cancer

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Mitomycin
    • Cisplatin
    • Fluorouracil
    Czechia Estonia France Hungary Italy Latvia +5
Previous Page
1 2 3 4

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!